THE FIRST EXPERIENCE OF TELBIVUDINE THERAPY IN LIVER TRANSPLANT PATIENTS
https://doi.org/10.15825/1995-1191-2010-1-33-37
Abstract
The first Russian experience of using telbivudine in liver transplant patients discussed in this article. Goal of telbivudine therapy in patients after liver transplantation was a prophylaxis and treatment of chronic hepatitis B recurrence. First data were received after 12 months since start of therapy, viral replication was inhibited, and that was similar with GLOBE trial results published at 2009.
About the Authors
O. A. Gerasimova
Russian Scientific Centre for Radiology and Surgical Technology, Saint Petersburg
Russian Federation
Russian Federation
D. A. Granov
Russian Scientific Centre for Radiology and Surgical Technology, Saint Petersburg
Russian Federation
Russian Federation
F. K. Zherebtsov
Russian Scientific Centre for Radiology and Surgical Technology, Saint Petersburg
Russian Federation
Russian Federation
V. V. Borovik
Russian Scientific Centre for Radiology and Surgical Technology, Saint Petersburg
Russian Federation
Russian Federation
References
1. Ganem D., Prince A. Hepatitis B virus infection – natural history and clinical consequences // New Engl. J. Med. 2004. Vol. 50 (11). P.1118–1129.
2. Furrington L., Hutin I., Bell B. The contribution of virus B hepatitis and hepatitis C virus infections to cir- rhosis and primary liver cancer worldwide // J. Hepatol. 2006. Vol. 45 (4). P. 529–538.
3. Liaw Y., Tai D., Chu C. et al. The development of cirrho- sis in patients with chronic type B hepatitis: a prospec- tive study // Hepatology. 1988. Vol. 8 (3). P. 493–496.
4. Futtovch G. Natural history of hepatitis B // J. Hepatol. 2003. Vol. 39 (Suppl. 1). P. 50–58.
5. Ochubo K., Cuto Y., Ichikawa T. et al. Viral load is a significant prognostic factor for hepatitis B virus – asso- ciated hepatocellular carcinoma // Cancer. 2002. Vol. 94. P. 2663–2668.
6. Ikeda K., Saitoh S., Suzuki Y. et al. Disease progres- sion and hepatocellular cancerogenesis in patients with chronic viral hepatitis: prospective observation 2215 pa- tients // J. Hepatol. 1998. Vol. 28 (6). P. 930–938.
7. Sagnelli E., Coppola N., Scolatico C. et al. Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis // Hepatology. 2000. Vol. 32 (5). P. 1106–1110.
8. Iloeje U., Yang H., Su J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load // Gastroenterology. 2006. Vol. 130 (3). P. 678–686.
9. Liaw Y., Leung N., Guan R. et al. Asian-pacific consen- sus statement on management of chronic hepatitis B: an update // J. Gastroenterol. and Hepatol. 2003. Vol. 18 (3). P. 239–245.
10. Novartis pharmaceuticals Corp. Tyzeka (telbivudine) Tablets. Prescribig information. Cambrige MA, USA, Index Pharmaceuticals, Inc., East Hanover, NJ., USA, 2006.
11. Hache C., Villaneuve J. Lamivudine treatment in patient with chronic hepatitis B and cirrhosis // Expert Opin. Pharmacother. 2006. Vol. 7 (13). P. 1835–1843.
12. Liaw Y., Leung N., Chang T. et al. Effects of extended la- mivudine therapy in Asian patients with chronic hepatitis B // Gastroenterology. 2000. Vol. 119 (1). P. 172–180.
13. Marcellin P., Chang T., Lim S. et al. Adefovir dipivoxil for the treatment of hepatitis B antigen positive chronic hepatitis B // New Engl. J. Med. 2003. Vol. 348. P. 808– 816.
14. Hadziyannis S., Tassopoulus N., Ting-Tsung C. et al. Long term adefovir dipivoxil treatment with HBe-Ag – negative chronic hepatitis B results after 5 years of ther- apy // Hepatology. 2005. Vol. 42. Р. 754A.
15. Yang H., Qi X., Sabogal A. et al. Cross-resistant testing of next generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiviral. Ther. 2005. Vol. 10 (5). P. 625–633.
16. Liaw Y., Gane E., Leung N. et al. 2-year GLOBE Trial Results: Telbivudine is superior to Lamivudine in pa- tients with chronic hepatitis B // Gastroenterology. 2009. Vol. 136. P. 486–495.
17. Ruiz-Sancho A., Sheldon J., Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B // Ex- pert Opin. Biol. Ther. 2007. Vol. 7 (5). P. 751–761.
Review
For citations:
Gerasimova O.A., Granov D.A., Zherebtsov F.K., Borovik V.V. THE FIRST EXPERIENCE OF TELBIVUDINE THERAPY IN LIVER TRANSPLANT PATIENTS. Russian Journal of Transplantology and Artificial Organs. 2010;12(1):33-37. (In Russ.) https://doi.org/10.15825/1995-1191-2010-1-33-37
Views:
608
Email this article 